Cargando…

Investigating Organ Toxicity Profile of Tenofovir and Tenofovir Nanoparticle on the Liver and Kidney: Experimental Animal Study

Tenofovir nanoparticles are novel therapeutic intervention in human immunodeficiency virus (HIV) infection reaching the virus in their sanctuary sites. However, there has been no systemic toxicity testing of this formulation despite global concerns on the safety of nano drugs. Therefore, this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peter, Aniekan Imo, Naidu, Edwin CS, Akang, Edidiong, Ogedengbe, Oluwatosin O, Offor, Ugochukwu, Rambharose, Sanjeev, Kalhapure, Rahul, Chuturgoon, Anil, Govender, Thirumala, Azu, Onyemaechi O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Toxicology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057299/ https://www.ncbi.nlm.nih.gov/pubmed/30057696 http://dx.doi.org/10.5487/TR.2018.34.3.221

Ejemplares similares

Nephrotoxicity and highly active antiretroviral therapy: Mitigating action of Momordica charantia
por: Offor, Ugochukwu, et al.
Publicado: (2018)

Renal histopathological and biochemical changes following adjuvant intervention of Momordica charantia and antiretroviral therapy in diabetic rats
por: Offor, Ugochukwu, et al.
Publicado: (2019)

Coconut Oil Extract Mitigates Testicular Injury Following Adjuvant Treatment with Antiretroviral Drugs
por: Ogedengbe, Oluwatosin O, et al.
Publicado: (2016)

Histo-morphological and seminal evaluation of testicular parameters in diabetic rats under antiretroviral therapy: interactions with Hypoxis hemerocallidea
por: Olasile, Ismail Onanuga, et al.
Publicado: (2018)

Hypoxis hemerocallidea alters metabolic parameters and hepatic histomorphology in streptozotocin-nicotinamide-induced diabetic male rats under antiretroviral therapy
por: Onanuga, Ismail Olasile, et al.
Publicado: (2018)

Effect of long-term administration of Cinnamomum cassia silver nanoparticles on organs (kidneys and liver) of Sprague-Dawley rats
por: KOUAME, Kofi, et al.
Publicado: (2018)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection: Microbiologic perspectives and anatomic considerations for sanctuary sites
por: Azu, Onyemaechi O., et al.
Publicado: (2021)

Tenofovir-silver nanoparticles conjugate ameliorates neurocognitive disorders and protects ultrastructural and cytoarchitectonic properties of the prefrontal cortex in diabetic rats
por: Lawal, Sodiq Kolawole, et al.
Publicado: (2022)

Hepatic histomorphological and biochemical changes following highly active antiretroviral therapy in an experimental animal model: Does Hypoxis hemerocallidea exacerbate hepatic injury?
por: Azu, Onyemaechi Okpara, et al.
Publicado: (2016)

Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats
por: Olojede, Samuel Oluwaseun, et al.
Publicado: (2022)

Sex determination using humeral dimensions in a sample from KwaZulu-Natal: an osteometric study
por: Ogedengbe, Oluwatosin Olalekan, et al.
Publicado: (2017)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Choice of speciality amongst first-year medical students in the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal
por: Azu, Onyemaechi O., et al.
Publicado: (2013)

Post-treatment with Telfairia occidentalis seed oil attenuates alcohol-induced testicular damage in Sprague-Dawley rats
por: Ayodele Oremosu, Ademola, et al.
Publicado: (2013)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Ganciclovir–tenofovir interaction leading to tenofovir-induced nephrotoxicity
por: Soanker, Radhika, et al.
Publicado: (2014)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Tenofovir and Severe Symptomatic Hypophosphatemia
por: Kichloo, Asim, et al.
Publicado: (2019)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Chemoenzymatic Synthesis of Tenofovir
por: Zdun, Beata, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
por: Dobard, Charles W, et al.
Publicado: (2015)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
por: Seo, Jun-Won, et al.
Publicado: (2020)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Tenofovir Nephrotoxicity: 2011 Update
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2011)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
por: Schafer, Jason J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e2grp1avnhu1l0vrisr12r36r9